- CD19: a biomarker for B cell development, lymphoma diagnosis and . . .
CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling
- CD19 - Lab Results explained | HealthMatters. io
The CD19 antigen (aka B-lymphocyte antigen CD19 or Cluster of Differentiation 19) plays an important role in clinical oncology It’s a protein found on the surface of B-cells, a type of white blood cell
- CD19 - an overview | ScienceDirect Topics
CD19 antigen, a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily, is encoded by the CD19 gene localized on 16p11 2 It aids in the stimulation of B cells and the development of an immunological response (Wang, Wei, Liu, 2012)
- Pathology Outlines - CD19
Defects in CD19 cause immunodeficiency common variable type 3 (OMIM #613493), characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen
- CD19 – MyPathologyReport
CD19 is a protein primarily expressed on the surface of B cells, a type of white blood cell that plays a key role in the immune system’s defense against infections
- BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 . . .
Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and
- Efficacy and safety of a novel CD19, CD22 dual-targeted fully human . . .
Background Chimeric antigen receptor (CAR) T-cell therapies targeting CD19 have demonstrated promising efficacy in treating refractory or relapsed B-cell malignancies Nonetheless, challenges such as antigen escape-mediated relapse and toxicities, including cytokine release syndrome (CRS) and neurotoxicity, may impede their clinical application Methods In this study, we developed a fully
- Researchers identify key B-cell lymphoma traits linked with greatest . . .
HOUSTON, JUNE 18, 2025 ― In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels of benefit from CD19 chimeric antigen receptor (CAR) T cell therapy
|